Xanthurenic acid translocates proapoptotic Bcl-2 family proteins into mitochondria and impairs mitochondrial function

Halina Z Malina*1 and Otto M Hess2

Address: 1Xanthurenic Acid Laboratory, Department Cardiology, Inselspital, CH-3010 Bern, Switzerland and 2Swiss Cardiovascular Research Center, University Hospital-Inselspital, CH-3010 Bern, Switzerland

Email: Halina Z Malina* - hmalina@hotmail.com; Otto M Hess - otto.martim.hess@insel.ch

* Corresponding author

Abstract

Background: Xanthurenic acid is an endogenous molecule produced by tryptophan degradation, produced in the cytoplasm and mitochondria. Its accumulation can be observed in aging-related diseases, e.g. senile cataract and infectious disease. We previously reported that xanthurenic acid provokes apoptosis, and now present a study of the response of mitochondria to xanthurenic acid.

Results: Xanthurenic acid at 10 or 20 µM in culture media of human aortic smooth muscle cells induces translocation of the proteins Bax, Bak, Bcl-xS, and Bad into mitochondria. In 20 µM xanthurenic acid, Bax is also translocated to the nucleus. In isolated mitochondria xanthurenic acid leads to Bax and Bcl-xS oligomerization, accumulation of Ca2+, and increased oxygen consumption.

Conclusion: Xanthurenic acid interacts directly with Bcl-2 family proteins, inducing mitochondrial pathways of apoptosis and impairing mitochondrial functions.

Background

Xanthurenic acid is an endogenous molecule derived from tryptophan degradation by indoleamine-2,3-dioxygenase. Indoleamine-2,3-dioxygenase is induced in infectious diseases by liposacharides, interferon-α, and superoxide radicals [1]. Xanthurenic acid is enzymatically formed by transamination of 3-hydroxykynurenine by kynurenine-aminotransferase [2]. Kynurenine-aminotransferase, has been cloned from mitochondria and cytoplasm [3,4]. Xanthurenic acid accumulates with age in senile cataract [5-7]. Previously, we reported that this acid leads to apoptotic-like cell death [8-10], its BH3 domain in the cytoplasm being responsible for targeting the protein to mitochondria, resulting in cytochrome c release [11,12]. We now report that proteins with a BH3-domain (Bax, Bak, Bcl-xS, Bad) are transformed in the presence of xanthurenic acid to their proapoptotic-inducing state and translocated to mitochondria. In vitro, xanthurenic acid leads to covalent oligomerization of Bax, and Bcl-xS. It also alters mitochondrial Ca2+ transport, and increases oxygen consumption.

Results

Xanthurenic acid provokes translocation of Bak, Bax, Bcl-xS, and Bad to mitochondria

The fate of Bax, Bak, Bcl-xS, and Bad in cultures of aortic human smooth muscle cells (HSMC) has been compared with control cells, using the antibody against Bax, which stains cells uniformly (Fig. 1A). 10 µM xanthurenic acid results in Bax being translocated to mitochondria (Fig.
1B), and at 20 µM, Bax seems to be translocated from mitochondria to nuclei (Fig. 1C). However, at the latter concentration, some Bax remained detectable in mitochondria (Fig. 1C). Granular bodies strongly staining with anti-Bax antibodies (green) were detected in the nucleus (Fig. 1C). Translocation of Bax to the nucleus during apoptosis has previously been reported [13]. Proapoptotic proteins Bak, Bcl-xs, and Bad (Fig. 2A, 2B, 2C) at 10 and 20 µM xanthurenic acid (Fig. 2D, 2E, 2F) were translocated into mitochondria.

Xanthurenic acid leads to oligomerization of cytoplasmic Bcl-x, and Bax in the rat liver mitochondrial fraction
Both Bcl-x and Bax were found in the 10,000 g mitochondrial fraction of rat liver. When it was incubated with xanthurenic acid at 5–10 µM (1 mg of protein/ml), cleavage of Bax with formation of p18 was observed. Both anti-Bax and anti-Bcl-x recognized the N-terminal part of the proteins, suggesting that the cleavage was more towards the C-terminal domain. When the concentration of xanthurenic acid was increased to 20–40 µM (1 mg protein/ml), Bax dimerized (Fig. 3A). Western blot analysis showed an increase of staining and dimerization of Bcl-x in the presence of xanthurenic acid (Fig. 3B). In the mitochondrial fraction, incubation of Bcl-x and Bax with xanthurenic acid led to stronger attachment of the correspondent IgG antibody than in control cells, indicating some form of posttranscriptional modification. Dimers of the proapoptotic proteins in the presence of xanthurenic acid showed up on SDS-PAGE, confirming the formation of covalent crosslinking. Bax and Bcl-x were faintly detectable in the mitochondrial pellets. Cytochrome c release was observed in the same protein extract (Fig. 3C).

Mitochondrial Ca2+ release
Ca2+ release was measured with Arsenazo III at a wavelength of 685/675 nm, using an Aminco DW-2 spectrophotometer. Xanthurenic acid at 15 µM (1 mg protein/ml) did not alter the release of Ca2+, but inhibition did occur at 66 µM (1 mg protein/ml). Ca2+ retained in mitochondria at this concentration was liberated after addition of 1 µM carbonyl cyanide-m-chlorophenylhydrazone (CCCP), which is known to provoke a loss of potential across mitochondrial membranes (Fig. 4). These results indicate that xanthurenic acid is involved in the modification of mitochondrial Ca2+ release, but does not lead to a loss of the mitochondrial membrane potential.

Consumption of O2 by mitochondria in the presence of xanthurenic acid
Consumption of O2 was measured with a Clarke-type electrode (Fig. 5). Mitochondrial respiration was supported with 2.5 mM potassium succinate prior to xanthurenic acid being added at 0.4 (Fig. 5, curve 1) or 4 µM (Fig. 5, curve 2). Xanthurenic acid stimulated oxygen consumption in a concentration-dependent manner.

Discussion
Apoptosis in the presence of xanthurenic acid is associated with cytochrome c release [8-10]. Our investigations show that xanthurenic acid induces the translocation of proapoptotic Bcl-2 proteins to mitochondria. A posttranscriptional modification of these proteins is suggested by the
direct crosslinking of Bax and Bcl-\textsubscript{x} in isolated mitochondria. Previously, BID was reported to change the conformation of Bax [14]. Recently, we reported that accumulation of xanthurenic acid in cells interrupts the interaction of Bad with signalling proteins of the 14-3-3 family [10]. However, here we have shown that Bax is dimerized in isolated mitochondria, indicating that xanthurenic acid itself induces a conformational change of the proteins. Using Western blotting, Bax in mitochondria incubated with xanthurenic acid was detected more readily than in controls. This phenomenon was previously reported to indicate a change in Bax folding which results in a better exposition of the N-terminal part of Bax for the antibody after exposure to apoptotic stimuli [15]. Furthermore, xanthurenic acid appeared to modify the folding of proteins [16], which could be the reason for the increased IgG binding to proteins in the presence of xanthurenic acid.

Our results indicate that xanthurenic acid is an endogenous crosslinker of Bax and Bcl-\textsubscript{x} proteins with a BH3 domain. Xanthurenic acid leads to translocation of BH3 proteins into mitochondria in human smooth muscle aortic cells. However, in isolated mitochondria, dimerized Bax and Bcl-\textsubscript{x}, found in the mitochondrial supernatant, are almost undetectable in the pellets, indicating that an additional cytoplasmic protein is necessary for translocation of these proteins into mitochondrial membranes. Therefore, the observed cytochrome c release in the presence of xanthurenic acid in isolated mitochondria is not mediated by Bax dimerization. At lower concentrations of xanthurenic acid, cleavage of Bax produced p18, which has been previously shown to enhance apoptosis [17]. Bax dimerization also has been shown to induce caspase-independent cell death [18]. Xanthurenic acid at 20 \textmu M causes Bax translocation into the nucleus, and plays a key role in apoptosis, because Bax/Bak deficient cells were
resistant to the apoptotic stimuli staurosporine and etoposide [19]. The fact that xanthurenic acid can directly provoke Bax and Bcl-xs crosslinking suggests that an accumulation of xanthurenic acid in a cell is sufficient to induce the cell death. Xanthurenic acid might be oxidized in vivo to its semiquinone, and further to quinone-di-oxo-xanthurenic acid, as previously described [6]. The semiquinone is an oxidative stress [20], which can lead to uncoupling of mitochondria, characterized by an increase of O2 consumption; in keeping, we noted an increased consumption of O2 in the presence of xanthurenic acid. Previously it was reported that Bax is only toxic in the presence of active oxidative phosphorylation [21]. Our results indicate that at 20 µM xanthurenic acid, Bax is translocated into the nucleus and Ca2+ release from mitochondria is blocked. Xanthurenic acid accumulation in mitochondria does not affect mitochondrial membrane potential, because Ca2+ was accumulated in the mitochondria and CCCP was able to release Ca2+ under these conditions. Previously it was reported that Bax/Bax-induced apoptosis was associated with an uptake of mitochondrial Ca2+ by an unknown mechanism. An excessive Ca2+ load may induce apoptosis by stimulating the release of apoptosis-promoting factors from the mitochondrial membrane space to the cytoplasm, leading to impaired mitochondrial function (for review [22]).

The results presented here indicate that the accumulation of xanthurenic acid in the human aortic smooth muscle cell causes a proapoptotic conformation of the mitochondrial proteins, Bax, Bak, Bcl-xL, and Bad. It was previously reported, that mitochondrial Bax plays an essential role in cytochrome c release, which can occur via Ca2+-dependent and -independent mechanisms [23]. Bax-driven apoptosis may be important for development of diabetes, atherosclerosis and neurological disorder [24-28]. We surmise that an accumulation of the endogenous aromatic amine, xanthurenic acid, may lead to organ failure.

**Materials and methods**

**Reagents**

The following polyclonal antibodies were obtained from Santa Cruz Biotechnology Inc. CA, USA: antibody against cytochrome c, against N-terminal part of Bax, Bak, Bcl-xL, and Bad. IgG secondary antibodies–Texas Red conjugated were from Santa Cruz or secondary antibodies IgG–Alexa 488 conjugated Molecular Probes (Leiden, The Netherlands). Carbonyl cyanide-m-chlorophenylhydrazone (CCCP) and Arsenazo III were from Sigma.

**Preparation of human smooth muscle cells primary culture**

The normal human aortic smooth muscle cells were from PromoCell GmbH, Heidelberg, Germany.

The cells were cultivated in Smooth Muscle Cells Growth Medium 2 (SMCGM2) with an addition of Supplement Pack/Smooth Muscle Cells (PromoCell). Cells were grown under a humidified atmosphere of 5% CO2 in air at 37°C. When confluent, they were incubated for 96 hours in the SMCGM2 or this medium supplemented with 10 and 20 µM xanthurenic acid. A 20 mM stock solution of xanthurenic acid was prepared in 0.5 M NaHCO3, and diluted in 0.01 M PBS pH 7.4.

**Western blot analysis of protein from rat liver mitochondrial fraction**

Rat liver mitochondria (80–90 mg protein per ml) were isolated, as described previously [29]. The 10,000 g mitochondrial fraction of cells was used (referred herein as mitochondria). The mitochondria were in MSH buffer.

---

**Figure 3**

Western blot analysis of supernatant from rat liver mitochondria incubated for 1 h in the presence of xanthurenic acid for Bax, Bcl-xL and cytochrome c; (A-B) Western blot analysis of Bax and Bcl-xL: lane 1-control mitochondria; lanes 2–5: mitochondria incubated in the presence of xanthurenic acid at concentration 5; 10; 20; and 40 µM per mg of protein (A) Bax; (B) Bcl-xL, (C) release of cytochrome c from mitochondria in the presence of xanthurenic acid at the same concentrations as in (A-B).
Ca$^{2+}$ release from mitochondria in the presence of xanthurenic acid (1) control mitochondria, (2, 3) in the presence of xanthurenic acid, and 1 mg of mitochondrial proteins: (2) 15 µM xanthurenic acid, (3) in the presence of 66 µM xanthurenic acid (4) after addition of CCCP to (3).

Immunofluorescence studies

Cells grown on glass coverslips were fixed for 10 min at room temperature in 4% paraformaldehyde in 0.1 M PIPES, pH 6.8, washed in PBS and permeabilized for 5 min in PIPES containing 0.05% saponin (65 µl per coverslip), washed in PBS, incubated for 10 min in cold acetone for additional fixing and permeabilisation, and again washed in PBS. Cells were incubated for 1.5 h with the first antibody diluted in PBS containing 1% bovine serum albumin, and after further washing incubated for 1.5 h with the secondary antibody. The coverslips were washed in PBS and incubated for 10 min with 65 µl of solution containing 1 µl of Hoechst 33342 dye (1 mg/ml), washed in PBS, and incubated with Antifade Kits (Molecular Probes, Leiden, The Netherlands) according to the supplier’s instruction.
Figure 5
Mitochondrial oxygen consumption in presence of xanthurenic acid per 1 mg of protein in the presence of (1) 0.4 μM xanthurenic acid, and (2) 4 μM xanthurenic acid.

Measurement of calcium uptake and release and O2 consumption in liver mitochondria in the presence of xanthurenic acid
An AminoCo DW-2A spectrophotometer was used at 685–675 nm the presence of 50 μM Arzenazo III, and mitochondrial respiration was measured using a Clarke-electrode as described previously [29]. Briefly, mitochondria (1 mg of mitochondrial protein/ml) were energized with 2.5 mM potassium succinate in the presence of rotenone. After Ca2+ uptake was complete, the uptake blocker, ruthenium red (RR), was added to see net release Ca2+ in the presence or absence of xanthurenic acid.

Competing interests
None declared.

Authors' contribution
HZM: conception, design, data collection and analysis, writing the paper.

OMH: revising the paper, research funds collection.

All authors approved the final version of the paper.

Acknowledgements
This work was supported by grant awarded to H. Z. M. by the Swiss National Science Foundation (32-59183.99), Swiss Heart Foundation, and MSE-Pharmaceutika GMBH, Bad Homburg, Germany. We thank Dr. C. Richter for proofreading the manuscript and Dr. M. Salvi for his help with Ca2+ release experiment.

References
1. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC: Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. *Experientia* 1989, 45:335-541.
2. Tobes MC, Kyrenurenine-oxoglutarate aminotransferase from rat kidney. *Methods Enzymol* 1987, 142:217-224.
3. Moso M, Cozzi L, Breton J, Speciale C, Okuno E, Schwarcz R, Benatti L: Molecular cloning of rat kyreneine aminotransferase: identity with glutamine transaminase K. *FEBS Lett* 1994, 353:21-24.
4. Malherbe P, Alberati-Giani D, Kohler C, Cesura AM: Identification of a mitochondrial form of kyreneine aminotransferase/glutamine transaminase K from rat brain. *FEBS Lett* 1995, 367:141-144.
5. Malina HZ, Martin XD: Deamination of 3-hydroxykynurenine in bovine lenses: a possible mechanism of cataract formation in general. *Graefes Arch Clin Exp Ophthalmol* 1995, 233:38-44.
6. Malina HZ, Martin XD: Xanthurenic acid derivative formation in the lens is responsible for senile cataract in humans. *Graefes Arch Clin Exp Ophthalmol* 1996, 234:723-730.
7. Malina HZ, Martin XD: 3-hydroxykynurenine transamination leads to the formation of the fluorescent substances in human lenses. *Eur J Ophthalmol* 1996, 6:250-256.
8. Malina HZ, Richter C, Martin XD: Mechanisms of pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. *BMC Physiol* 2001, 1(7).
9. Malina HZ, Richter C, Frueh B, Hess OM: Lens epithelial cell apoptosis and intracellular Ca2+ increase in the presence of xanthurenic acid. *BMC Ophthalmol* 2002, 2(1).
10. Malina HZ, Frueh BE: Abnormal signalling of 14-3-3 proteins in cells with accumulated xanthurenic acid. *Biochem Biophys Res Commun* 2003, 310:646-650.
11. Luo X, Budhidarlo I, Zou H, Slaughter C, Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell* 1998, 94:481-490.
12. Pollster BM, Kinnaly KW, Fiskum G: BM3 death domain peptide induces cell type-selective mitochondrial outer membrane permeabilization. *J Biol Chem* 2001, 276:37887-37894.
13. Gajkowski B, Motyl T, Olszewska-Badarzuk H, Gniadecki R, Koronkiewicz M: Structural association of Bax with nuclear matrix and cytomatrix revealed by embedment-free immunogold electron microscopy. *Cell Biol Int* 2000, 24:649-656.
14. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC: Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. *J Cell Biol* 1999, 144:891-901.
15. Priault M, Camougrand N, Chaudhuri B, Manon S: A role for the C-terminal domain of Bax and Bcl-XL in their localization and function in yeast cells. *FEBS Lett* 1999, 442:225-228.
16. Malina HZ: Xanthurenic acid provokes formation of unfolded proteins in endoplasmic reticulum of the lens epithelial cells. *BMC Physiol* 1999, 2(6):600-605.
17. Wood DE, Newcomb EW: Cleavage of Bax enhances its cell death function. *Exp Cell Res* 2000, 256:375-382.
18. Gross A, Jockel J, Wei MC, Korsmeyer SJ: Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. *Embo J* 1998, 17:3878-3885.
19. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsokopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* 2001, 292:727-730.
20. Gutierrez PL: The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review. *Free Radic Biol Med* 2000, 29:263-275.
21. Harris MH, Vander Heiden MG, Kwon SJ, Thompson CB: Role of oxidative phosphorylation in Bax toxicity. *Mol Cell Biol* 2000, 20:3590-3596.
22. Hajnoczky G, Davies E, Madesh M: Calcium signaling and apoptosis. *Biochem Biophys Res Commun* 2003, 304:445-454.
23. Gogvadze V, Robertson JD, Zhivotovsky B, Orrenius S: Cytochrome c release occurs via Ca2+-dependent and Ca2+-independent mechanisms that are regulated by Bax. *J Biol Chem* 2001, 276:9066-9071.
24. Konstadoulakis MM, Kymionis GD, Karagiani M, Katergianakis V, Doundoulakis N, Pararas V et al. Evidence of apoptosis in human carotid atheroma. J Vasc Surg 1998, 27:733-739.
25. Podesta F, Romeo G, Liu WH, Krajewski S, Reed JC, Gerhardinger C, Lorenzi M: Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol 2000, 156:1025-1032.
26. Snider BJ, Goztron FJ, Choi DW: Apoptosis and necrosis in cerebrovascular disease. Ann N Y Acad Sci 1999, 893:243-253.
27. Srinivasan S, Stevens M, Wiley JW: Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000, 49:1932-1938.
28. Hayakawa Y, Takemura G, Misao J, Kanoh M, Ohno M, Ohashi H et al: Apoptosis and overexpression of bax protein and bax mRNA in smooth muscle cells within intimal hyperplasia of human radial arteries: analysis with arteriovenous fistulas used for hemodialysis. Arterioscler Thromb Vasc Biol 1999, 19:2066-207.
29. Frei B, Winterhalter KH, Richter C: Mechanism of alloxan-induced calcium release from rat liver mitochondria. J Biol Chem 1985, 260:7394-7401.